Sustainability in Asthma and COPD Drug Development with Chiesi’s Diego Ardigò — Episode 259

Key Takeaways

• Inhaler sustainability is becoming a regulatory and market differentiator
• Device design now co‑developed with formulation for optimal patient use
• Patient adherence data directly influences R&D investment decisions
• Chiesi sees respiratory R&D as a template for broader pharma innovation

Pulse Analysis

The respiratory market is at a crossroads where clinical efficacy must coexist with environmental stewardship. Traditional metered‑dose inhalers rely on propellants that contribute significantly to greenhouse gas emissions, prompting regulators in Europe and North America to push for low‑impact alternatives. Companies like Chiesi are investing in dry‑powder and soft‑mist technologies that eliminate propellants, positioning themselves ahead of upcoming compliance deadlines while appealing to eco‑conscious prescribers and patients.

Beyond the hardware, the drug‑device synergy is reshaping R&D pipelines. Formulation scientists collaborate early with engineers to ensure that active pharmaceutical ingredients maintain stability and bioavailability within new device architectures. This integrated approach shortens development timelines and reduces costly late‑stage failures, a critical advantage in the competitive asthma and COPD space where generic pressure is intense. Moreover, real‑world data on inhaler technique and adherence is feeding back into design iterations, creating a virtuous cycle of patient‑centric innovation.

The broader pharmaceutical industry can extract several lessons from this evolution. First, sustainability is no longer a peripheral concern but a core strategic pillar that influences investor sentiment and market access. Second, cross‑functional collaboration—uniting formulation, device engineering, and behavioral science—delivers products that meet both clinical and environmental benchmarks. Finally, leveraging patient behavior analytics can sharpen portfolio decisions, ensuring resources flow toward therapies that promise long‑term adherence and health outcomes. As the sector embraces these principles, the balance between innovation, sustainability, and patient care will define the next generation of respiratory therapeutics.